Clinical Trials Logo

Filter by:
NCT ID: NCT03919383 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Phase II of Lenvatinib Plus Toripalimab for Advanced HCC

Start date: April 15, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with toripalimab in patients with advanced hepatocellular carcinoma (HCC)

NCT ID: NCT04199520 Withdrawn - Clinical trials for Stage IV Breast Cancer

Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients

Start date: April 15, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the effect of primary resection combined with systemic therapy and pure systemic therapy on the overall survival of patients with stage Ⅳ breast cancer.

NCT ID: NCT04311242 Withdrawn - Epilepsy Clinical Trials

Microbiome Composition and Biomarker Discovery in Refractory Pediatric Epilepsy

Start date: April 15, 2020
Phase:
Study type: Observational

Research study to look for bio markers in epilepsy patients on ketogenic diet

NCT ID: NCT03709550 Withdrawn - Clinical trials for Castration-Resistant Prostate Carcinoma

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Start date: April 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of decitabine and how well it works when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread to other places in the body. Androgen can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of androgen made by the body. Decitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving decitabine and enzalutamide may work better in treating participants with castration resistant prostate cancer.

NCT ID: NCT04151563 Withdrawn - Clinical trials for Carcinoma, Non-small Cell Lung Cancer

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

CheckMate 79X
Start date: April 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy

NCT ID: NCT04818736 Withdrawn - Clinical trials for Vaccine Preventable Disease

COVID-19 Vaccine For Indirect Protection

Start date: April 15, 2021
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to test whether vaccinating adults ≥18 years in Hutterite colonies with mRNA-1273 (Moderna COVID-19) vaccine as compared to control (usual care) can prevent RT-PCR confirmed COVID-19 in non-vaccinated Hutterite members.

NCT ID: NCT04260776 Withdrawn - Clinical trials for Tobacco Use Disorder

Adaptive Treatment Strategies for Improving Engagement With a Web-Based Smoking Intervention in Socially Anxious Smokers

Start date: April 15, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial will use a pilot sequential multiple assignment randomized trial (SMART) to examine protocol feasibility and acceptability of new components of a web-based intervention for socially anxious smokers. This study will be used to help build an adaptive treatment strategy to improve engagement with and effectiveness of the web-based intervention. Adaptive treatment strategies provide individualized sequences of intervention components to accommodate the changing needs of individuals based on their characteristics, treatment response, or engagement.

NCT ID: NCT05261646 Withdrawn - Clinical trials for Chemotherapy-Induced Thrombocytopenia

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Start date: April 15, 2022
Phase: Phase 3
Study type: Interventional

The study is aimed to evaluate the efficacy of different doses of hetrombopag compared to placebo, measured by the proportion of subjects that can complete two planned consecutive chemotherapy cycles with no modification of chemotherapy regimen (i.e., delayed start, dose reduction, omission, or discontinuation) because of thrombocytopenia [platelet count <100×109/L], to determine an optimal dose of hetrombopag and to demonstrate its superiority over placebo.

NCT ID: NCT04357951 Withdrawn - Tourette Syndrome Clinical Trials

D-cycloserine Augmented Treatment for Youth With Tic Disorders

Start date: April 15, 2023
Phase: Early Phase 1
Study type: Interventional

This pilot study aims evaluate the feasibility and initial efficacy of behavior therapy augmented by d-cycloserine (DCS) compared to behavior therapy augmented by placebo. After an initial assessment to determine eligibility, youth with TD will be randomly assigned to receive four sessions of behavior therapy augmented by either DCS or placebo. D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. The investigators' proof-of-concept work has found that a single session of DCS-augmented behavior therapy reduced the severity of tics targeted in treatment on the Hopkins Motor/Vocal Tic Scale (HM/VTS) compared to placebo-augmented behavior therapy. This highlights the exciting potential of combining DCS with behavior therapy to improve reductions in tic severity. However, prior to a large-scale clinical trial, it is essential to determine the feasibility and efficacy of augmenting behavior therapy with DCS over multiple treatment sessions.

NCT ID: NCT05541393 Withdrawn - COVID-19 Clinical Trials

Engaging Church Health Ministries to Decrease Coronavirus Disease-19 Vaccine Hesitancy in Underserved Populations

ENGAGE
Start date: April 15, 2023
Phase: N/A
Study type: Interventional

This study will determine the effectiveness of training church health ministers to educate their congregations about the safety and efficacy of COVID-19 vaccines and booster shots for decreasing vaccine hesitancy and improving testing knowledge in underserved Black communities.